Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

GSK hiring 130 at inhaler facility, even as CRO axes up to 200 GSK alum

GlaxoSmithKline, which has been laying off hundreds of employees in the face of falling Advair sales, is adding up to 140 employees at a facility in North Carolina. But it is a bittersweet turn of events since as many as 200 former GSK workers in the area who moved to jobs with CRO Parexel are getting their pink slips.

125 ex-GSK R&D staffers in RTP face the ax--again

Eight months after the ax dropped late last year, 125 former GlaxoSmithKline staffers in Research Triangle Park found their jobs back on the chopping block Thursday as their new employer at Parexel included them in a lineup of new layoffs.

Aegerion's embattled CEO Beer steps down

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Aegerion dumps CEO who got it into FDA trouble for talking too freely

Aegerion Pharmaceuticals CEO Marc Beer may be a fast talker but he has been a bit of a slow walker when it comes to giving up his position as CEO. The executive, who got the company into trouble with the feds for speaking too freely on TV about the upside of his company's lead drug, has acquiesced to investor demands and moved on.

Denali names Carole Ho its head of development

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Abrupt departure of Novogen CEO followed upbeat Anisina presentation

The abrupt departure of Australia's Novogen Chairman Graham Kelly this week came after the jointly listed Nasdaq and Australian Stock Exchange biotech presented details of an in vivo proof of concept study for anti-tropomyosin drug candidate Anisina in July in the U.S.

Australia's Novogen says CEO Kelly out, interim CEO Ross named

Australia's Novogen, listed on the Nasdaq and Australia Stock Exchange, said CEO Graham Kelly has resigned and that Iain Ross will take an acting role in the post until a permanent appointment is made.

Singapore's biopharma industry: Where the jobs are

Hays Recruiting in Singapore says jobs in biopharma niches in manufacturing, regulatory and sales are up for grabs in the island nation, topping its latest quarterly regional outlook of skills in demand through September 2015, according to a press release.

Biogen R&D chief Williams leaves for biotech startup

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

UPDATED: Biogen R&D chief Doug Williams joins exodus to run a biotech upstart

Biogen's high-profile R&D chief, Doug Williams, has heard the siren song of a biotech startup. Near midday on Friday, the Big Biotech put out word that Williams will be leaving Biogen to helm a fledgling, and unnamed, company. All that is known now is that Williams is the first member of a new company that will focus on cancer diagnostics and therapies.